The Development of Animal Models of Inflammatory Bowel Disease

References

• Sadlack B., Merz H., Schorle H., Schimpl A., Feller A. C., Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993; 75(2)253–61
   PubMed Web of Science ®Google Scholar
• Kuhn R., Lohler J., Rennick D., Rajewsky K., Mullen W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75(2)263–74
   PubMed Web of Science ®Google Scholar
• Powrie F., Correa-Oliveira R., Mauze S., Coffman R. L. Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J. Exp. Med. 1994; 179(2)589–600
   Google Scholar
• Mombaerts P., Mizoguchi E., Grusby M. J., Glimcher L. H., Bhan A. K., Tonegawa S. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 1993; 75(2)274–82
   Google Scholar
• Sartor R. B., Rath H. C., Lichtman S. N., van Tol E. A. Animal models of intestinal and joint inflammation. Baillieres Clin. Rheumatol. 1996; 10(1)55–76
   Google Scholar
• Hugot J. P., Laurent-Puig P., Gower-Rousseau C., Olson J. M., Lee J. C., Beaugerie L., Naom I., Dupas J. L., Van Gossum A., Orholm M., Bonaiti-Pellie C., Weissenbach J., Mathew C. G., Lennard-Jones I. E., Cortot A., Colombel J. F., Thomas G. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996; 379(6568)821–3
   PubMed Web of Science ®Google Scholar
• Brant S. R., Fu Y., Fields C. T., Baltazar R., Ravenhill G., Pickles M. R., Rohal P. M., Mann J., Kirschner B. S., Jabs E. W., Bayless T. M., Hanauer S. B., Cho J. H. American families with Crohn's disease have strong evidence for linkage to chromosome 16 but not chromosome 12. Gastroenterology 1998; 115(5)1056–61
   Google Scholar
• Cho J. H., Nicolae D. L., Gold L. H., Fields C. T., LaBuda M. C., Rohal P. M., Pickles M. R., Qin L., Fu Y., Mann J. S., Kirschner B. S., Jabs E. W., Weber J., Hanauer S. B., Bayless T. M., Brant S. R. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc. Natl. Acad. Sci. USA 1998; 95(13)7502–7
   Google Scholar
• Ohmen J. D., Yang H. Y., Yamamoto K. K., Zhao H. Y., Ma Y., Bentley L. G., Huang Z., Gerwehr S., Pressman S., McElree C., Targan S., Rotter J. I., Fischel-Ghodsian N. Susceptibility locus for inflammatory bowel disease on chromosome 16 has a role in Crohn's disease, but not in ulcerative colitis. Hum. Mol. Genet. 1996; 5(10)1679–83
   PubMed Web of Science ®Google Scholar
• Curran M. E., Lau K. F., Hampe J., Schreiber S., Bridger S., Macpherson A. J., Cardon L. R., Sakul H., Harris T. J., Stokkers P., Van Deventer S. J., Mirza M., Raedler A., Kruis W., Meckler U., Theuer D., Herrmann T., Gionchetti P., Lee J., Mathew C., Lennard-Jones J. Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16. Gastroenterology 1998; 115(5)1066–71, (a) V. Binder Genetic epidemiology in inflammatory bowel disease. Dig. Dis. 1999, 16(6): 351–5
   Google Scholar
• Singleton J. W. Clinical features, laboratory findings and course in ulcerative colitis. Inflammatory Bowel Disease, J. B. Kirsner, R. G. Shorter. Lea & Febiger, Philadelphia 1988; 167–174
   Google Scholar
• Lightdale C. J., Sherlock P. Neoplasia and gastrointestinal malignancy in inflammatory bowel disease. Inflammatory Bowel Disease, J. B. Kirsner, R. G. Shorter. Lea & Febiger, Philadelphia 1988; 281–298
   Google Scholar
• Greenstein A. J., Sachar D. B., Smith H., Janowitz H. D., Aufses A. H., Jr. Patterns of neoplasia in Crohn's disease and ulcerative colitis. Cancer 1980; 46(2)403–7
   Google Scholar
• Sugita A., Sachar D. B., Bodian C., Ribeiro M. B., Aufses A. H., Jr., Greenstein A. J. Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age at onset on colitis-cancer interval. Gut 1991; 32(2)167–9
   Google Scholar
• Glotzer D. J. The surgical management of idiopathic inflammatory bowel disease. Inflammatory Bowel Disease, J. B. Kirsner, R. G. Shorter. Lea & Febiger, Philadelphia 1988; 585–644
   Google Scholar
• Fanner R. G. Clinical features, laboratory findings and course of Crohn's disease. Inflammatory Bowel Disease, J. B. Kirsner, R. G. Shorter. Lea & Febiger, Philadelphia 1988; 175–183
   Google Scholar
• Fanner R. G., Hawk W. A., Turnbull R. B., Jr. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology 1975; 68: 627–35
   PubMed Web of Science ®Google Scholar
• Fanner R. G. Clinical features and natural history of inflammatory bowel disease. Med. Clin. North Am. 1980; 64: 1103–15
   Google Scholar
• Greenberger N. J. Indications for surgery in inflammatory bowel disease: a gastroenterologist's opinion. Inflammatory Bowel Disease, J. B. Kirsner, R. G. Shorter. Lea & Febiger, Philadelphia 1988; 529–547
   Google Scholar
• Bayless T. M., Picco M. F., LaBuda M. C. Genetic anticipation in Crohn's disease. Am. J. Gastroenterol. 1998; 93(12)2322–5, (a) J.M. Polito 2nd, B. Childs, E.D. Mellits, A.Z. Tokayer, M.L. Harris and T.M. Bayless. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology 1996, 111(3): 580–6; (b) T.M. Bayless, A.Z. Tokayer, J.M. Polito 2nd, S.A. Quaskey, E.D. Mellits and M.L. Harris. Crohn's disease: concordance for site and clinical type in affected family members - potential hereditary influences. Gastroenterology 1996, 111(3): 573–9
   Google Scholar
• Satsangi J., Landers C. J., Welsh K. I., Koss K., Targan S., Jewell D. P. The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease. Inflamm. Bowel Dis. 1998; 4(1)18–26, (a) A. Saxon, F. Shanahan, C. Landers, T. Ganz and S. Targan. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J. Allergy Clin. Immunol. 1990, 86(2): 202–10
   Google Scholar
• Das K. M., Dasgupta A., Mandal A., Geng X. Autoimmunity to cytoskeletal protein tropomyosin. A clue to the pathogenetic mechanism for ulcerative colitis. J. Immunol. 1993; 150(6)2487–93
   Google Scholar
• Quinton J. F., Sendid B., Reumaux D., Duthilleul P., Cortot A., Grandbastien B., Charrier G., Targan S. R., Colombel J. F., Poulain D. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42(6)788–91, (a) B. Sendid, J.F. Colombel, P.M. Jacquinot, C. Faille, J. Fruit, A. Cortot, D. Lucidarme, D. Camus and D. Poulain. Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin. Diagn. Lab. Immunol. 1996, 3(2): 219–26
   PubMed Web of Science ®Google Scholar
• Yang H., Rotter J. I. Genetics of inflammatory bowel disease. The Genetic Basis of Common Disease, R. King, J. I. Rotter, A. Motulsky. Oxford University Press, Oxford 1992; 32–64
   Google Scholar
• Duerr R. Genetics of inflammatory bowel disease. Inflammatory Bowel Diseases 1996; 2: 48–60
   PubMedGoogle Scholar
• Plevy S. E., Targan S. R., Yang H., Fernandez D., Rotter J. I., Toyoda H. Tumor necrosis factor microsatellites define a Crohn's disease-associated haplotype on chromosome 6. Gastroenterology 1996; 110: 1053–60
   PubMedGoogle Scholar
• Challacombe S. J., Tomasi T. B. Systemic tolerance and secretory immunity after oral immunization. J. Exp. Med. 1980; 152: 1459–72
   PubMed Web of Science ®Google Scholar
• Mowat A. M. The role of antigen recognition and suppressor cells in mice with oral tolerance to ovalalbumin. Immunology 1985; 56: 253
   Google Scholar
• Mattingly J. A., Waksman B. H. Immunologic suppression after oral administration of antigen. I. Specific suppressor cells formed rat Peyer's patches after oral administration. J. Immunol. 1978; 123: 2344
   Google Scholar
• Khoury S. J., Hancock W. W., Weiner H. L. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med. 1992; 176: 1355–64, (a) A. Miller, A. al-Sabbagh, L.M. Santos, M.P. Das and H.L. Weiner. Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression. J. Immunol. 1993, 151(12): 7307–15; (b) L.K. Richman, A.S. Graeff, R. Yarchoan and W. Strober. Simultaneous induction of antigen-specific IgA helper T cells and IgG suppressor T cells in the murine Peyer's patch after protein feeding. J. Immunol. 1981, 126: 2079–83; (c) L.M. Santos, A. al-Sabbagh, A. Londono and H.L. Weiner. Oral tolerance to myelin basic protein induces regulatory TGF-beta-secreting T cells in Peyer's patches of SJL mice. Cell. Immunol. 1994, 157: 439–47; (d) A. Friedman and H.L. Weiner. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc. Natl. Acad. Sci. USA 1994, 91: 6688–92
   PubMed Web of Science ®Google Scholar
• Zeitz M., Ullrich R., Schneider T., Schieferdecker H. L., Riecken E. O. Cell differentiation and proliferation in the gastrointestinal tract with respect to the local immune system. Am. NY Acad. Sci. 1994; 733: 75–86
   Google Scholar
• Mueller C., Knoflach P., Zielinski. T-cell activation in Crohn's disease: Increased levels of soluble interleukin-2 receptor in serum and in serum supernatants of stimulated peripheral blood mononuclear cells. Gastroenterology 1990; 98: 639–46
   PubMed Web of Science ®Google Scholar
• Schumann G., Betzler M., Post S., Herfarth C., Meuer S. Soluble interleukin-2 receptor, interleukin-6 and interleukin-1 beta in patients with Crohn's disease and ulcerative colitis: preoperative levels and postoperative changes of serum concentrations. Digestion 1992; 51(1)51–9
   Google Scholar
• Mayer L., Eisenhardt D. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J. Clin. Invest. 1990; 86: 1255–60
   PubMed Web of Science ®Google Scholar
• Mullin G. E., Lazenby A. J., Harris M. L., Bayless T. M., James S. P. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology 1992; 102(5)1620–7
   Google Scholar
• James S. P., Mullin G. E., Kanof M. E., Zeitz M. Role of lymphokines in immunoregulatory function of mucosal T cells in humans and nonhuman primates. Immunol. Res. 1991; 10(3,4)230–8
   Google Scholar
• Mullin G. E. Expression of Th2 cytokines in the lamina propria in patients with IBD. J. Inflamm. Bowel Disease 1996
   Google Scholar
• Salomon P., Pizzimenti A., Panja A., Reisman A., Mayer L. The expression and regulation of class II antigens in normal and inflammatory bowel disease peripheral blood monocytes and intestinal epithelium. Autoimmunity 1991; 9: 141–9, (a) K. Kusugami, J. Haruta, M. Ieda, M. Shinoda, T. Ando, A. Kuroiwa, K. Ina, H. Iokawa, A. Ishihara, S. Sarai et al. Phenotypic and functional characterization of T-cell lines generated from colonoscopic biopsy specimens in patients with ulcerative colitis. Dig. Dis. Sci. 1995, 40: 198–210
   PubMed Web of Science ®Google Scholar
• Stronkhorst A., Radema S., Yong S. L., Bijl H., Ten Berge I. J., Tytgat G. N., van Deventer S. J. CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study. Gut 1997; 40(3)320–7, (a) C. van Montfrans, L. Camogho and S.J. van Deventer. Immunotherapy of Crohn's disease. Mediators Inflamm. 1998, 7(3): 149–52
   PubMed Web of Science ®Google Scholar
• Lichtiger S., Present D. H., Kornbluth A., et al. Cyclosporin in sever ulcerative colitits refractory to steroid therapy. N. Eng. J. Med. 1994; 330: 1841–5
   PubMed Web of Science ®Google Scholar
• Hodgson H. D.F., Wands J. R., Isselbacher K. J. Decreased suppressor cell activity in inflammatory bowel disease. Clin. Exp. Immunol. 1978; 32: 451
   PubMed Web of Science ®Google Scholar
• Kelleher D., Murphy A., Whelan C. A., Feighery C., Weir D. G., Keeling P. W.N. Defective suppression in the autologous mixed lymphocyte reaction in patients with Crohn's disease. Gut 1989; 30: 839–44
   Google Scholar
• Mayer L., Eisenhardt D. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J. Clin. Invest. 1990; 86(4)1255–60
   Google Scholar
• Hogaboam C. M., Vallance B. A., Kumar A., Addison C. L., Graham F. L., Gauldie J., Collins S. M. Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease. J. Clin. Invest. 1997; 100(11)2766–76
   PubMed Web of Science ®Google Scholar
• Hermiston M. L., Gordon J. I. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995; 270: 1203–7
   PubMed Web of Science ®Google Scholar
• Podolsky D. K. Lessons from genetic models of inflammatory bowel disease. Acta Gastroenterol. Belg. 1997; 60: 163–5
   Google Scholar
• May G. R., Sutherland L. R., Meddings J. B. Is small intestinal permeability really increased in relatives of patients with Crohn's disease. Gastroenterology 1993; 104: 1627–32, (a) R.J. Hilsden, J.B. Meddings and L.R. Sutherland. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. Gastroenterology 1996, 110: 1395–1403
   PubMed Web of Science ®Google Scholar
• Powrie F., Leach M. W., Mauze S., Menon S., Caddie L. B., Coffman R. L. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994; 1(7)553–62
   PubMed Web of Science ®Google Scholar
• Targan S. R., Hanauer S. B., van Deventer S. J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 1997; 337: 1029–35
   PubMed Web of Science ®Google Scholar
• Sellon R. K., Tonkonogy S., Schultz M., Dieleman L. A., Grenther W., Balish E., Rennick D. M., Sartor R. B. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect. Immun. 1998; 66(11)5224–31, (a) Y. Cong, S.L. Brandwein, R.P. McCabe, A. Lazenby, E.H. Birkenmeier, J.P. Sundberg and C.O. Elson. CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J. Exp. Med. 1998, 187(6): 855–64
   PubMed Web of Science ®Google Scholar
• Rath H. C., Herfarth H. H., Ikeda J. S., Grenther W. B., Hamm T. E., Jr., Balish E., Taurog J. D., Hammer R. E., Wilson K. H., Sartor R. B. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J. Clin. Invest. 1996; 98(4)945–53
   PubMed Web of Science ®Google Scholar
• Duchmann R., Schmitt E., Knolle P., Meyer zum Buschenfelde K. H., Neurath M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur. J. Immunol. 1996; 26(4)934–8
   PubMed Web of Science ®Google Scholar